Sweden's OssDsign Q2 sales rise 2.4% gross margin falls
Sweden's OssDsign Q2 sales rise 2.4% gross margin falls
Overview
Sweden orthobiologics products developer's Q2 net sales grew 2.4% yr/yr
Gross margin for Q2 was 92.1%, down from 96.8% last year due to mix effects
Company reported wider operating loss and lower operating expenses yr/yr
Outlook
Company did not provide specific guidance for future quarters or the full year
Result Drivers
PRODUCT AND CUSTOMER MIX - Co said gross margin decline was due to changes in product and customer mix
LOWER SALES VARIABLE COSTS - Co said reduction in sales variable costs partly offset gross profit shortfall
OPERATING EXPENSES DOWN - Co reported lower operating expenses as sales variables cost declined, while non-sales variable costs were flat yr/yr
Company press release: ID:nWkr9vVwDT
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Miss | SEK 37.78 mln | SEK 38.60 mln (2 Analysts) |
Q2 Loss Per Share |
| SEK 0.10 |
|
Q2 Net Loss |
| SEK 11.41 mln |
|
Q2 Gross Margin |
| 92.10% |
|
Q2 Operating Profit |
| -SEK 12.35 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for OssDsign AB is SEK12.00, about 185.7% above its August 17 closing price of SEK4.20
Reuters Recommended Reads
Aug 17 - China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
Aug 18 - Switzerland's SKAN Group H1 net sales rise on Services & Consumables growth, acquisitions
Aug 17 - InspireMD Q2 revenue beats estimates on international demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)